March 17 (Reuters) - GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did notshow any new safety problems in treating asthma, a preliminaryreview by U.S. Food and Drug Administration staff found.
The review comes two days ahead of a meeting of FDA advisersto discuss the combination treatment, Breo Ellipta, andrecommend whether or not it should be approved to treat asthma.
The FDA staff also said, in documents released on Tuesday,that FDA advisers would discuss the fact that the benefit of oneof the components in the treatment was not demonstratedconsistently. (http://1.usa.gov/1Fvj3r9) (Reporting by Vidya L Nathan and Amrutha Penumudi in Bengaluru;Editing by Savio D'Souza)